Chief Medical Officer

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Spyre Therapeutics reports Q2 EPS (49c), consensus (71c)

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Grants of Inducement Awards

Director, Drug Safety Physician

Spyre Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory bowel disease and other immune-mediated conditions. The Director, Drug Safety Physician will be instrumental in advancing the company's antibody portfolio by overseeing safety reporting, conducting safety assessments, and ensuring compliance with global regulatory requirements.

Sign up with Google

Sign in with Google